CliffBio
small molecule

ENTRESTO SPRINKLE

SACUBITRIL; VALSARTAN

Loss of exclusivityFebruary 2037latest FDA-listed patent expiry
CompanyNovartis →View the full company profile on CliffBio

Drug detail

Brand nameENTRESTO SPRINKLE
Active ingredientSACUBITRIL; VALSARTAN
Strength6MG;6MG
Dosage formCAPSULE, PELLETS
RouteORAL
ModalitySmall molecule
FDA approvalApril 2024
Marketing statusRX

Listed patents

PatentExpiresType
10722471February 2037product
8877938May 2027substance, product
9388134November 2026use U-1723

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ENTRESTO SPRINKLE patent cliff — loss of exclusivity February 2037 | CliffBio